Verapamil is contraindicated in ventricular tachycardia, which is the most probable diagnosis.

Managing Ventricular Tachycardia

Ventricular tachycardia is a type of rapid heartbeat that originates in the ventricles of the heart. In a peri-arrest situation, it is assumed to be ventricular in origin. If the patient shows adverse signs such as low blood pressure, chest pain, heart failure, or syncope, immediate cardioversion is necessary. However, in the absence of such signs, antiarrhythmic drugs may be used. If drug therapy fails, electrical cardioversion may be needed with synchronised DC shocks.

There are several drugs that can be used to manage ventricular tachycardia, including amiodarone, lidocaine, and procainamide. Amiodarone is ideally administered through a central line, while lidocaine should be used with caution in severe left ventricular impairment. Verapamil should not be used in VT. If drug therapy fails, an electrophysiological study (EPS) may be conducted, or an implantable cardioverter-defibrillator (ICD) may be implanted. The ICD is particularly indicated in patients with significantly impaired LV function.

Given the patient’s syncope, low BP, and regular wide complex tachycardia, which is likely to be ventricular tachycardia, the appropriate next step is DC cardioversion since the systolic BP is below 90 mmHg. Adenosine is not relevant in this scenario as it is used for managing narrow complex regular tachycardia with no adverse features. Amiodarone is an antiarrhythmic medication that could be used to treat ventricular tachycardia, but it is not appropriate in this case due to the patient’s syncope and low BP.

Management of Peri-Arrest Tachycardias

The Resuscitation Council (UK) guidelines for the management of peri-arrest tachycardias have been simplified in the 2015 update. The previous separate algorithms for broad-complex tachycardia, narrow complex tachycardia, and atrial fibrillation have been replaced by a unified treatment algorithm. After basic ABC assessment, patients are classified as stable or unstable based on the presence of adverse signs such as hypotension, pallor, sweating, confusion, or impaired consciousness. If any of these signs are present, synchronised DC shocks should be given, up to a maximum of three shocks.

The treatment following this is based on whether the QRS complex is narrow or broad and whether the rhythm is regular or irregular. For broad-complex tachycardia, a loading dose of amiodarone followed by a 24-hour infusion is given if the rhythm is regular. If the rhythm is irregular, expert help should be sought as it could be due to atrial fibrillation with bundle branch block, atrial fibrillation with ventricular pre-excitation, or torsade de pointes.

For narrow-complex tachycardia, vagal manoeuvres followed by IV adenosine are given if the rhythm is regular. If unsuccessful, atrial flutter is considered, and rate control is achieved with beta-blockers. If the rhythm is irregular, it is likely due to atrial fibrillation, and electrical or chemical cardioversion is considered if the onset is less than 48 hours. Beta-blockers are usually the first-line treatment for rate control unless contraindicated. The full treatment algorithm can be found on the Resuscitation Council website.

Prosthetic Heart Valves: Options for Replacement

Prosthetic heart valves are commonly used to replace damaged aortic and mitral valves. There are two main options for replacement: biological (bioprosthetic) or mechanical. Biological valves are usually sourced from bovine or porcine origins and are commonly used in older patients. However, they have a major disadvantage of structural deterioration and calcification over time. On the other hand, mechanical valves have a low failure rate but require long-term anticoagulation due to the increased risk of thrombosis. Warfarin is still the preferred anticoagulant for patients with mechanical heart valves, and the target INR varies depending on the valve type. Aspirin is only given in addition if there is an additional indication, such as ischaemic heart disease. Following the 2008 NICE guidelines, antibiotics are no longer recommended for common procedures such as dental work for prophylaxis of endocarditis.

Marfan Syndrome: A Connective Tissue Disorder with Cardiovascular Manifestations

Marfan syndrome is an autosomal dominant connective tissue disorder that presents with a wide range of clinical manifestations. The ocular, skeletal, and cardiovascular systems are characteristically involved. Aortic root dilatation, occurring in 70-80% of cases, is the most common cardiovascular manifestation, followed by mitral valve prolapse at 60-70%. Mitral annular calcification is less common, occurring in 8-15% of cases. Aortic dissection, accounting for around 5% of all cases, is more likely in patients with Marfan syndrome, especially those with severe aortic root dilatation.

The weakening of the aortic media leads to a fusiform ascending aortic aneurysm, which may be complicated by aortic regurgitation and aortic dissection. Mitral regurgitation can result from mitral valve prolapse, dilatation of a mitral valve annulus, or mitral annular calcification. Pregnancy is particularly hazardous for patients with Marfan syndrome. Treatment with β blockers can reduce the rate of aortic dilatation and the risk of rupture.

If a patient has poorly controlled hypertension and is already taking an ACE inhibitor, calcium channel blocker, and a standard-dose thiazide diuretic, and their potassium level is above 4.5mmol/l, the best option is to add an alpha- or beta-blocker. According to NICE guidelines, this patient has resistant hypertension, which is stage 4 of the NICE flowchart for hypertension management. Spironolactone can also be introduced at this stage, but only if the patient’s serum potassium is less than 4.5mmol/l, as spironolactone is a potassium-sparing diuretic. Indapamide is not suitable for someone who is already taking a thiazide diuretic like bendroflumethiazide. Furosemide is typically used for hypertension management in patients with heart failure or kidney disease, which is not present in this case. Hydralazine is primarily used for emergency hypertension management or hypertension during pregnancy, not for long-term management.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

Understanding ECG Findings in Acute Pericarditis

Acute pericarditis is a condition that commonly presents with central pleuritic chest pain, relieved on leaning forward. One of the main ECG findings in acute pericarditis is widespread concave ST-segment elevations with PR-segment depression, which is 85% specific for the condition. Absent P waves are not typically caused by acute pericarditis, and ST-segment elevation in the anterior leads is more suggestive of anterior myocardial infarction. U waves are not characteristic ECG findings in acute pericarditis and are associated with other conditions. Other clinical features of acute pericarditis are largely dependent on the underlying cause. It is important to understand these ECG findings to aid in the diagnosis and management of acute pericarditis.

Treatment Options for Uncontrolled Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health complications if left untreated. When first-line treatment with an angiotensin-converting enzyme (ACE) inhibitor is not effective, there are several options for adjusting medication to better control blood pressure.

Switching to a calcium-channel blocker like amlodipine is recommended as a second-line treatment. Thiazide-like diuretics may also be considered. For patients over 55 years old without diabetes, or those of black African or Afro-Caribbean family origin without diabetes, calcium-channel blockers should be started as first-line treatment.

Increasing the dose of perindopril erbumine beyond the maximum of 8 mg is not safe and may cause renal impairment. Adding atenolol is reserved for patients with known coronary artery disease or inadequately controlled hypertension on maximal doses of other medications.

Thiazide diuretics like bendroflumethiazide are no longer recommended by NICE guidance. Instead, thiazide-like diuretics such as indapamide are recommended as a second-line alternative to calcium-channel blockers if hypertension is not adequately controlled on maximal doses of first-line treatment.

If blood pressure remains uncontrolled despite medication adjustments, referral for ambulatory blood pressure monitoring may be necessary to determine the best course of action.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

Cardiac Abnormalities Associated with Marfan Syndrome

Marfan syndrome is commonly associated with cardiac abnormalities, with aortic root dilatation being the most prevalent, found in approximately 80% of cases. This can lead to aortic regurgitation and even dissection. While there is some evidence of a slight increase in atrial septal defects in Marfan syndrome patients, it is not as common as aortic regurgitation or mitral valve prolapse. Dilated cardiomyopathy can also present in Marfan syndrome patients, although it is not as prevalent as aortic root dilatation or regurgitation. Pulmonary regurgitation is also increased in incidence in Marfan syndrome, but it is still less common than aortic regurgitation. Finally, while persistent ductus arteriosus is more commonly found in Marfan syndrome patients than in the general population, the association is relatively weak. Overall, Marfan syndrome patients should be monitored closely for these cardiac abnormalities to ensure proper management and treatment.

To manage a postpartum haemorrhage, an ABCDE approach should be taken, with initial steps including compressing the uterus and catheterising the patient. This is known as ‘mechanical management’ and is appropriate for a primary postpartum haemorrhage (PPH) where uterine atony is the most common cause. IV warmed crystalloid should also be given. Medical management options such as IV oxytocin or IM/IV carboprost should only be considered if mechanical methods fail. It is important to note that IV carboprost should not be administered as it can lead to serious side effects.

Understanding Postpartum Haemorrhage

Postpartum haemorrhage (PPH) is a condition where a woman experiences blood loss of more than 500 ml after giving birth vaginally. It can be classified as primary or secondary. Primary PPH occurs within 24 hours after delivery and is caused by the 4 Ts: tone, trauma, tissue, and thrombin. The most common cause is uterine atony. Risk factors for primary PPH include previous PPH, prolonged labour, pre-eclampsia, increased maternal age, emergency Caesarean section, and placenta praevia.

In managing PPH, it is important to involve senior staff immediately and follow the ABC approach. This includes two peripheral cannulae, lying the woman flat, blood tests, and commencing a warmed crystalloid infusion. Mechanical interventions such as rubbing up the fundus and catheterisation are also done. Medical interventions include IV oxytocin, ergometrine, carboprost, and misoprostol. Surgical options such as intrauterine balloon tamponade, B-Lynch suture, ligation of uterine arteries, and hysterectomy may be considered if medical options fail to control the bleeding.

Secondary PPH occurs between 24 hours to 6 weeks after delivery and is typically due to retained placental tissue or endometritis. It is important to understand the causes and risk factors of PPH to prevent and manage this life-threatening emergency effectively.

To improve control of hypertension in patients who are already taking an ACE inhibitor or an angiotensin receptor blocker, the 2019 NICE guidelines recommend adding either a calcium channel blocker (such as amlodipine) or a thiazide-like diuretic (such as indapamide). This is a change from previous guidelines, which only recommended adding a calcium channel blocker in this situation.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

Management of Bradycardia in Peri-Arrest Rhythms

The 2015 Resuscitation Council (UK) guidelines highlight the importance of identifying adverse signs and potential risk of asystole in the management of bradycardia in peri-arrest rhythms. Adverse signs indicating haemodynamic compromise include shock, syncope, myocardial ischaemia, and heart failure. Atropine (500 mcg IV) is the first line treatment in this situation. If there is an unsatisfactory response, interventions such as atropine (up to a maximum of 3mg), transcutaneous pacing, and isoprenaline/adrenaline infusion titrated to response may be used. Specialist help should be sought for consideration of transvenous pacing if there is no response to the above measures.

Furthermore, the presence of risk factors for asystole such as complete heart block with broad complex QRS, recent asystole, Mobitz type II AV block, and ventricular pause > 3 seconds should be considered. Even if there is a satisfactory response to atropine, specialist help is indicated to consider the need for transvenous pacing. Effective management of bradycardia in peri-arrest rhythms is crucial in preventing further deterioration and improving patient outcomes.

Admission to hospital is necessary for this patient as they are a suitable candidate for electrical cardioversion.

Atrial Fibrillation and Cardioversion: Elective Procedure for Rhythm Control

Cardioversion is a medical procedure used in atrial fibrillation (AF) to restore the heart’s normal rhythm. There are two scenarios where cardioversion may be used: as an emergency if the patient is haemodynamically unstable, or as an elective procedure where a rhythm control strategy is preferred. In the elective scenario, cardioversion can be performed either electrically or pharmacologically. Electrical cardioversion is synchronised to the R wave to prevent delivery of a shock during the vulnerable period of cardiac repolarisation when ventricular fibrillation can be induced.

According to the 2014 NICE guidelines, rate or rhythm control should be offered if the onset of the arrhythmia is less than 48 hours, and rate control should be started if it is more than 48 hours or is uncertain. If the AF is definitely of less than 48 hours onset, patients should be heparinised and may be cardioverted using either electrical or pharmacological means. However, if the patient has been in AF for more than 48 hours, anticoagulation should be given for at least 3 weeks prior to cardioversion. An alternative strategy is to perform a transoesophageal echo (TOE) to exclude a left atrial appendage (LAA) thrombus. If excluded, patients may be heparinised and cardioverted immediately.

NICE recommends electrical cardioversion in this scenario, rather than pharmacological. If there is a high risk of cardioversion failure, it is recommended to have at least 4 weeks of amiodarone or sotalol prior to electrical cardioversion. Following electrical cardioversion, patients should be anticoagulated for at least 4 weeks. After this time, decisions about anticoagulation should be taken on an individual basis depending on the risk of recurrence.

During advanced ALS, the recommended dose of adrenaline to administer is 1mg. If the patient is identified in the hospital, they should receive a minimum shock of 150 joules (unless the defibrillator model specifies otherwise). Compressions at a rate of 30:2 should be resumed for 2 minutes, followed by reassessment of the rhythm. If VF or pVT persists, a second shock should be given. Repeat the previous steps until the third shock, at which point 1mg IV of adrenaline and 300 mg IV of amiodarone should be administered while continuing CPR. Afterward, 1mg of adrenaline should be given after every other shock. Consider administering a second dose of amiodarone after a total of 5 defibrillation attempts if it is available. If amiodarone is not available, lidocaine can be used.

The 2015 Resus Council guidelines for adult advanced life support outline the steps to be taken when dealing with patients with shockable and non-shockable rhythms. For both types of patients, chest compressions are a crucial part of the process, with a ratio of 30 compressions to 2 ventilations. Defibrillation is recommended for shockable rhythms, with a single shock for VF/pulseless VT followed by 2 minutes of CPR. Adrenaline and amiodarone are the drugs of choice for non-shockable rhythms, with adrenaline given as soon as possible and amiodarone administered after 3 shocks for VF/pulseless VT. Thrombolytic drugs should be considered if a pulmonary embolus is suspected. Atropine is no longer recommended for routine use in asystole or PEA. Oxygen should be titrated to achieve saturations of 94-98% following successful resuscitation. The Hs and Ts should be considered as potential reversible causes of cardiac arrest.

In cases of sudden atrial fibrillation, if the duration is 48 hours or more, the first step is to control the heart rate. If long-term rhythm control is being considered, it is important to wait at least 3 weeks after starting therapeutic anticoagulation before attempting cardioversion.

Atrial fibrillation (AF) is a condition that requires careful management to prevent complications. The latest guidelines from NICE recommend that patients presenting with AF should be assessed for haemodynamic instability, and if present, electrically cardioverted. For haemodynamically stable patients, the management depends on how acute the AF is. If the AF has been present for less than 48 hours, rate or rhythm control may be considered. However, if it has been present for 48 hours or more, or the onset is uncertain, rate control is recommended. If long-term rhythm control is being considered, cardioversion should be delayed until the patient has been maintained on therapeutic anticoagulation for at least 3 weeks.

Rate control is the first-line treatment strategy for AF, except in certain cases. Medications such as beta-blockers, calcium channel blockers, and digoxin can be used to control the heart rate. However, digoxin is no longer considered first-line as it is less effective at controlling the heart rate during exercise. Rhythm control agents such as beta-blockers, dronedarone, and amiodarone can be used to maintain sinus rhythm in patients with a history of AF. Catheter ablation is recommended for those who have not responded to or wish to avoid antiarrhythmic medication.

The aim of catheter ablation is to ablate the faulty electrical pathways that are causing AF. The procedure is performed percutaneously, typically via the groin, and can use radiofrequency or cryotherapy to ablate the tissue. Anticoagulation should be used 4 weeks before and during the procedure. It is important to note that catheter ablation controls the rhythm but does not reduce the stroke risk, so patients still require anticoagulation as per their CHA2DS2-VASc score. Complications of catheter ablation can include cardiac tamponade, stroke, and pulmonary vein stenosis. The success rate of the procedure is around 50% for early recurrence within 3 months, and around 55% of patients who’ve had a single procedure remain in sinus rhythm after 3 years. Of patients who’ve undergone multiple procedures, around 80% are in sinus rhythm.

When beta-blockers fail to control angina, it is recommended to supplement with a dihydropyridine calcium channel blocker that has a longer duration of action.

Angina pectoris is a condition that can be managed through various methods, including lifestyle changes, medication, percutaneous coronary intervention, and surgery. In 2011, NICE released guidelines for the management of stable angina. Medication is an important aspect of treatment, and all patients should receive aspirin and a statin unless there are contraindications. Sublingual glyceryl trinitrate can be used to abort angina attacks. The first-line medication should be either a beta-blocker or a calcium channel blocker, depending on the patient’s comorbidities, contraindications, and preferences. If a calcium channel blocker is used as monotherapy, a rate-limiting one such as verapamil or diltiazem should be used. If used in combination with a beta-blocker, a longer-acting dihydropyridine calcium channel blocker should be used. Beta-blockers should not be prescribed concurrently with verapamil due to the risk of complete heart block. If the initial treatment is not effective, medication should be increased to the maximum tolerated dose. If a patient is still symptomatic after monotherapy with a beta-blocker, a calcium channel blocker can be added, and vice versa. If a patient cannot tolerate the addition of a calcium channel blocker or a beta-blocker, other drugs such as long-acting nitrates, ivabradine, nicorandil, or ranolazine can be considered. Nitrate tolerance is a common issue, and patients who take standard-release isosorbide mononitrate should use an asymmetric dosing interval to maintain a daily nitrate-free time of 10-14 hours to minimize the development of nitrate tolerance. This effect is not seen in patients who take once-daily modified-release isosorbide mononitrate. If a patient is taking both a beta-blocker and a calcium-channel blocker, a third drug should only be added while awaiting assessment for PCI or CABG.

For primary prevention of cardiovascular disease, individuals with type 1 diabetes who do not have established risk factors should be prescribed atorvastatin 20mg if they are over 40 years old, have had diabetes for more than 10 years, have established nephropathy, or have other risk factors such as obesity and hypertension. As this patient has had type 1 diabetes for over 10 years, they should be offered statins.

Statins are drugs that inhibit the action of an enzyme called HMG-CoA reductase, which is responsible for producing cholesterol in the liver. However, they can cause some adverse effects such as myopathy, which includes muscle pain, weakness, and damage, and liver impairment. Myopathy is more common in lipophilic statins than in hydrophilic ones. Statins may also increase the risk of intracerebral hemorrhage in patients who have had a stroke before. Therefore, they should be avoided in these patients. Statins should not be taken during pregnancy and should be stopped if the patient is taking macrolides.

Statins are recommended for people with established cardiovascular disease, those with a 10-year cardiovascular risk of 10% or more, and patients with type 2 diabetes mellitus. Patients with type 1 diabetes mellitus who were diagnosed more than 10 years ago, are over 40 years old, or have established nephropathy should also take statins. It is recommended to take statins at night as this is when cholesterol synthesis takes place. Atorvastatin 20mg is recommended for primary prevention, and the dose should be increased if non-HDL has not reduced for 40% or more. Atorvastatin 80 mg is recommended for secondary prevention. The graphic shows the different types of statins available.

If a beta-blocker is not effective in controlling angina, it is recommended to add a longer-acting dihydropyridine calcium channel blocker such as amlodipine. Diltiazem and verapamil should not be used in combination with a beta-blocker due to the risk of life-threatening bradycardia and heart failure. Ivabradine and nicorandil can be used as alternatives if a dihydropyridine CCB is not suitable, but should only be initiated under specialist advice.

Angina pectoris is a condition that can be managed through various methods, including lifestyle changes, medication, percutaneous coronary intervention, and surgery. In 2011, NICE released guidelines for the management of stable angina. Medication is an important aspect of treatment, and all patients should receive aspirin and a statin unless there are contraindications. Sublingual glyceryl trinitrate can be used to abort angina attacks. The first-line medication should be either a beta-blocker or a calcium channel blocker, depending on the patient’s comorbidities, contraindications, and preferences. If a calcium channel blocker is used as monotherapy, a rate-limiting one such as verapamil or diltiazem should be used. If used in combination with a beta-blocker, a longer-acting dihydropyridine calcium channel blocker should be used. Beta-blockers should not be prescribed concurrently with verapamil due to the risk of complete heart block. If the initial treatment is not effective, medication should be increased to the maximum tolerated dose. If a patient is still symptomatic after monotherapy with a beta-blocker, a calcium channel blocker can be added, and vice versa. If a patient cannot tolerate the addition of a calcium channel blocker or a beta-blocker, other drugs such as long-acting nitrates, ivabradine, nicorandil, or ranolazine can be considered. Nitrate tolerance is a common issue, and patients who take standard-release isosorbide mononitrate should use an asymmetric dosing interval to maintain a daily nitrate-free time of 10-14 hours to minimize the development of nitrate tolerance. This effect is not seen in patients who take once-daily modified-release isosorbide mononitrate. If a patient is taking both a beta-blocker and a calcium-channel blocker, a third drug should only be added while awaiting assessment for PCI or CABG.

Choosing the Right Medication for Hypertension: A Guide

When it comes to treating hypertension, there are several medications to choose from. The National Institute for Health and Care Excellence (NICE) recommends an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) as first-line treatment for those under 55, while calcium channel blockers (CCBs) are preferred for patients over 55 and those of Afro-Caribbean origin. Beta blockers, once a common choice, are no longer recommended as first-line treatment.

If initial treatment is not effective, a thiazide diuretic can be added to an ACE inhibitor or ARB and CCB. Alpha blockers, such as doxazosin, are no longer commonly used for hypertension and are contraindicated in patients with urinary incontinence. Valsartan, an ARB, is an alternative for patients who cannot tolerate an ACE inhibitor.

For elderly patients with isolated systolic hypertension, a dihydropyridine CCB like amlodipine is the drug of choice, especially if thiazides are not an option. Beta blockers should be used with caution in patients with asthma and are not indicated in this case. By carefully considering the patient’s age, ethnicity, and medical history, healthcare providers can choose the most appropriate medication for treating hypertension.

Appropriate Laboratory Tests for Cardiovascular Health Check

To assess a patient’s cardiovascular health, various laboratory tests may be conducted. However, the choice of tests should be based on the patient’s symptoms, medical history, and physical examination. In the case of a patient with signs of hyperlipidaemia, a lipid profile would be the most appropriate test to diagnose familial hyperlipidaemia. On the other hand, an ECG would be indicated if there was a family history of sudden death to rule out underlying rhythm issues. A fasting glucose test would not be necessary in this case, but it may be conducted as part of a cardiovascular health check. A full blood count would not aid in the diagnosis of hyperlipidaemia, but it may be conducted if the patient was experiencing chest pain to exclude anaemia as a cause of his symptoms. Lastly, a renal profile would not aid in the diagnosis of familial hyperlipidaemia, but it may be conducted to rule out secondary causes if the patient were hypertensive.

Individuals with heart failure and an ejection fraction of 40% or lower should be prescribed an ACE inhibitor, unless there are contraindications or intolerance. This is supported by numerous clinical trials that have shown their efficacy in reducing hospital admissions and mortality rates. The dosage should be started low and gradually increased until the target dose or the highest tolerated dose is achieved, with regular monitoring of renal function and serum electrolytes.

Loop Diuretics: Mechanism of Action and Indications

Loop diuretics, such as furosemide and bumetanide, are medications that inhibit the Na-K-Cl cotransporter (NKCC) in the thick ascending limb of the loop of Henle. This reduces the absorption of NaCl and increases the excretion of water and electrolytes, making them effective in treating conditions such as heart failure and resistant hypertension. Loop diuretics act on NKCC2, which is more prevalent in the kidneys.

As loop diuretics work on the apical membrane, they must first be filtered into the tubules by the glomerulus before they can have an effect. This means that patients with poor renal function may require higher doses to achieve a sufficient concentration within the tubules.

Loop diuretics are commonly used in the treatment of heart failure, both acutely (usually intravenously) and chronically (usually orally). They are also effective in treating resistant hypertension, particularly in patients with renal impairment.

However, loop diuretics can have adverse effects, including hypotension, hyponatremia, hypokalemia, hypomagnesemia, hypochloremic alkalosis, ototoxicity, hypocalcemia, renal impairment (from dehydration and direct toxic effect), hyperglycemia (less common than with thiazides), and gout.

In summary, loop diuretics are effective medications for treating heart failure and resistant hypertension, but their use should be carefully monitored due to potential adverse effects. Patients with poor renal function may require higher doses to achieve therapeutic effects.

For a patient with poorly controlled moderate hypertension who is already taking an ACE inhibitor, calcium channel blocker, and thiazide diuretic, the recommended next step would be to add spironolactone if their potassium level is less than 4.5mmol/L. Atenolol may be considered as a fourth-line agent if the potassium level is over 4.5mmol/L, but spironolactone is preferred according to NICE guidelines. Hydralazine should not be used outside of specialist care, and indapamide is not the best option as the patient is already taking a thiazide diuretic. Prazosin is an alternative to spironolactone, but spironolactone is preferred given the lower potassium level.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

Reduced seizure threshold is a contraindication for the use of bupropion in patients with epilepsy.

NICE guidance recommends offering nicotine replacement therapy (NRT), varenicline, or bupropion to patients for smoking cessation, with no preference for one medication over another. NRT should be offered in combination for those with high nicotine dependence or inadequate response to single forms. Varenicline should be started a week before the target stop date and monitored for adverse effects, including nausea and suicidal behavior. Bupropion should also be started before the target stop date and is contraindicated in epilepsy, pregnancy, and breastfeeding. Pregnant women should be tested for smoking and referred to NHS Stop Smoking Services, with first-line interventions being cognitive behavior therapy, motivational interviewing, or structured self-help and support. NRT may be used if other measures fail, but varenicline and bupropion are contraindicated.

If a patient has a Wells’ score of 1 or less for a suspected DVT, the first step is to arrange a D dimer test with results available within 4 hours, according to NICE guidelines. In this case, the score of 1 is due to localized tenderness along the deep venous system, with no other risk factors present. A proximal leg vein ultrasound scan is not the first-line investigation option for a Wells’ score of 1 or less, and anticoagulant treatment should not be started without a D dimer test. If the D dimer results cannot be obtained within 4 hours, low molecular weight heparin injection may be considered, but therapeutic dose apixaban should not be started without a D dimer test.

NICE updated their guidelines on the investigation and management of venous thromboembolism (VTE) in 2020. The use of direct oral anticoagulants (DOACs) is recommended as first-line treatment for most people with VTE, including as interim anticoagulants before a definite diagnosis is made. Routine cancer screening is no longer recommended following a VTE diagnosis. The cornerstone of VTE management is anticoagulant therapy, with DOACs being the preferred choice. All patients should have anticoagulation for at least 3 months, with the length of anticoagulation being determined by whether the VTE was provoked or unprovoked.

For primary prevention of cardiovascular disease, a dosage of 20mg of atorvastatin is recommended. However, for secondary prevention, a higher dosage of 80 mg is recommended.

Statins are drugs that inhibit the action of an enzyme called HMG-CoA reductase, which is responsible for producing cholesterol in the liver. However, they can cause some adverse effects such as myopathy, which includes muscle pain, weakness, and damage, and liver impairment. Myopathy is more common in lipophilic statins than in hydrophilic ones. Statins may also increase the risk of intracerebral hemorrhage in patients who have had a stroke before. Therefore, they should be avoided in these patients. Statins should not be taken during pregnancy and should be stopped if the patient is taking macrolides.

Statins are recommended for people with established cardiovascular disease, those with a 10-year cardiovascular risk of 10% or more, and patients with type 2 diabetes mellitus. Patients with type 1 diabetes mellitus who were diagnosed more than 10 years ago, are over 40 years old, or have established nephropathy should also take statins. It is recommended to take statins at night as this is when cholesterol synthesis takes place. Atorvastatin 20mg is recommended for primary prevention, and the dose should be increased if non-HDL has not reduced for 40% or more. Atorvastatin 80 mg is recommended for secondary prevention. The graphic shows the different types of statins available.

Vagal manoeuvres, such as carotid sinus massage or the Valsalva manoeuvre, are the initial treatment for supraventricular tachycardia. Adenosine should only be administered if these manoeuvres are ineffective. According to the ALS guidelines, direct current cardioversion is not recommended for this condition.

Understanding Supraventricular Tachycardia

Supraventricular tachycardia (SVT) is a type of tachycardia that originates above the ventricles. It is commonly associated with paroxysmal SVT, which is characterized by sudden onset of a narrow complex tachycardia, usually an atrioventricular nodal re-entry tachycardia (AVNRT). Other causes include atrioventricular re-entry tachycardias (AVRT) and junctional tachycardias.

When it comes to acute management, vagal maneuvers such as the Valsalva maneuver or carotid sinus massage can be used. Intravenous adenosine is also an option, with a rapid IV bolus of 6mg given initially, followed by 12mg and then 18mg if necessary. However, adenosine is contraindicated in asthmatics, and verapamil may be a better option for them. Electrical cardioversion is another option.

To prevent episodes of SVT, beta-blockers can be used. Radio-frequency ablation is also an option. It is important to work with a healthcare provider to determine the best course of treatment for each individual case.

Overall, understanding SVT and its management options can help individuals with this condition better manage their symptoms and improve their quality of life.

Differential Diagnosis for a Patient with Dyspnoea and a Murmur: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy is a condition that can lead to sudden death in young athletes and is characterized by dyspnoea, LVH, and a loud S4. The systolic murmur associated with hypertrophic cardiomyopathy does not radiate to the carotids and can be differentiated from aortic stenosis, which causes a crescendo-decrescendo murmur that does radiate to the carotids. Young-onset hypertension is unlikely to cause a murmur, and acute myocardial infarction would show ST elevation or depression on ECG, but not LVH. Atrial septal defect is usually picked up in newborn checks and presents with a brief murmur in early systole and early diastole, while hypertrophic cardiomyopathy presents with a double or triple apical impulse and a characteristic jerky carotid pulse. It is important to recognize the symptoms and signs of hypertrophic cardiomyopathy to prevent sudden death in young athletes.

ECG Findings in Various Cardiovascular Conditions

New-onset left bundle branch block may indicate ischaemic heart disease and could be a sign of STEMI if the patient’s symptoms match the diagnosis. Pericarditis typically causes widespread ST elevation on an ECG. Mitral stenosis can lead to left atrial enlargement and potentially atrial fibrillation. Pulmonary embolism often results in a right bundle branch block or a right ventricular strain pattern of S1Q3T3. Tricuspid stenosis can also cause right ventricular strain. It’s worth noting that mitral stenosis, tricuspid stenosis, and secondary pulmonary hypertension due to PE are associated with right ventricular strain and hypertrophy with partial or complete right bundle branch block, while pericarditis is not typically associated with bundle branch block.

The ECG changes in this patient suggest pericarditis, given their young age, widespread ST-segment elevation, and normal troponin levels. While PR segment depression is typically seen in pericarditis, note that the PR segment may be elevated in aVR. Myocarditis would be a possible diagnosis if the troponin levels were elevated. Infective endocarditis is less likely due to the absence of fever and ECG changes consistent with pericarditis. Although cardiac tamponade is a potential complication of pericarditis, it is unlikely in this case as the patient’s blood pressure is normal and pulsus paradoxus is not present.

Understanding Acute Pericarditis

Acute pericarditis is a medical condition characterized by inflammation of the pericardial sac that lasts for less than 4-6 weeks. The condition can be caused by various factors such as viral infections, tuberculosis, uraemia, post-myocardial infarction, autoimmune pericarditis, radiotherapy, connective tissue disease, hypothyroidism, malignancy, and trauma. Symptoms of acute pericarditis include chest pain, non-productive cough, dyspnoea, and flu-like symptoms. Patients may also experience pericardial rub.

To diagnose acute pericarditis, doctors may perform an electrocardiogram (ECG) to check for changes in the heart’s electrical activity. Blood tests may also be conducted to check for inflammatory markers and troponin levels. Patients suspected of having acute pericarditis should undergo transthoracic echocardiography.

Treatment for acute pericarditis depends on the underlying cause. Patients with high-risk features such as fever or elevated troponin levels may need to be hospitalized. However, most patients with pericarditis secondary to viral infection can be managed as outpatients. Strenuous physical activity should be avoided until symptoms resolve and inflammatory markers normalize. A combination of nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine is typically used as first-line treatment for patients with acute idiopathic or viral pericarditis. The medication is usually tapered off over 1-2 weeks.

Overall, understanding acute pericarditis is important for prompt diagnosis and appropriate management of the condition.

Torsades de pointes can be treated with IV magnesium sulfate.

Torsades de Pointes: A Life-Threatening Condition

Torsades de pointes is a type of ventricular tachycardia that is associated with a prolonged QT interval. This condition can lead to ventricular fibrillation, which can cause sudden death. There are several causes of a prolonged QT interval, including congenital conditions such as Jervell-Lange-Nielsen syndrome and Romano-Ward syndrome, as well as certain medications like antiarrhythmics, tricyclic antidepressants, and antipsychotics. Other causes include electrolyte imbalances, myocarditis, hypothermia, and subarachnoid hemorrhage.

The management of torsades de pointes involves the administration of intravenous magnesium sulfate. This can help to stabilize the heart rhythm and prevent further complications.

Management of Bradycardia in Peri-Arrest Rhythms

The 2015 Resuscitation Council (UK) guidelines highlight the importance of identifying adverse signs and potential risk of asystole in the management of bradycardia in peri-arrest rhythms. Adverse signs indicating haemodynamic compromise include shock, syncope, myocardial ischaemia, and heart failure. Atropine (500 mcg IV) is the first line treatment in this situation. If there is an unsatisfactory response, interventions such as atropine (up to a maximum of 3mg), transcutaneous pacing, and isoprenaline/adrenaline infusion titrated to response may be used. Specialist help should be sought for consideration of transvenous pacing if there is no response to the above measures.

Furthermore, the presence of risk factors for asystole such as complete heart block with broad complex QRS, recent asystole, Mobitz type II AV block, and ventricular pause > 3 seconds should be considered. Even if there is a satisfactory response to atropine, specialist help is indicated to consider the need for transvenous pacing. Effective management of bradycardia in peri-arrest rhythms is crucial in preventing further deterioration and improving patient outcomes.

Possible Causes of Sudden-Onset Severe Back Pain: A Differential Diagnosis

Sudden-onset severe back pain can be a sign of various medical conditions. In the case of a male patient with increasing age and a known history of abdominal aortic aneurysm, a rupturing aortic aneurysm should be suspected until proven otherwise. This suspicion is supported by the presence of shock, a large palpable mass deep in the epigastrium, and severe back pain that may radiate to the abdomen. The risk of rupture increases with the size of the aneurysm, and blood initially leaks into the retroperitoneal space before spilling into the peritoneal cavity.

Other possible causes of sudden-onset severe back pain include acute cholecystitis, which is unlikely in a patient who had a previous cholecystectomy. Acute pancreatitis may also cause epigastric pain that radiates to the back, but this condition is usually accompanied by vomiting and diarrhea, and the patient does not have significant risk factors for it. Renal colic, which is characterized by acute severe pain that radiates from the loin to the groin, may cause tachycardia but is less likely in a patient who is haemodynamically unstable and has a known large AAA. Herniated lumbar disc, which may cause back pain that worsens with coughing or sneezing and radiates down the leg, is also less likely in this case.

Therefore, a rupturing abdominal aortic aneurysm is the most probable cause of the patient’s sudden-onset severe back pain, and urgent management is necessary to prevent further complications.

Assessing medications in elderly patients can be challenging, as they may be taking unnecessary or harmful drugs. The STOPP-START Criteria (Gallagher et al., 2008) provides guidance on medications that should be considered for discontinuation in the elderly. In this case, the patient has gout, which can be aggravated by bendroflumethiazide, an outdated thiazide diuretic that is no longer recommended by NICE. Additionally, her blood pressure is well below the target for her age, which is 150/90 mmHg in clinic. Ramipril is a more suitable antihypertensive medication to continue for now, but it may also be discontinued if her blood pressure remains low. The patient requires aspirin and atorvastatin for her ischemic heart disease, and allopurinol for her gout.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

The patient exhibits symptoms of congestive heart failure, which can be managed with loop diuretics and nitrates in acute or decompensated cases. However, these medications do not improve long-term survival. To reduce mortality in patients with left ventricular failure, ACE-inhibitors, beta-blockers, angiotensin receptor blockers, aldosterone antagonists, and hydralazine with nitrates have all been proven effective. Digoxin can reduce hospital admissions but not mortality, and is typically reserved for patients who do not respond to initial treatments or have co-existing atrial fibrillation.

Drug Management for Chronic Heart Failure: NICE Guidelines

Chronic heart failure is a serious condition that requires proper management to improve patient outcomes. In 2018, the National Institute for Health and Care Excellence (NICE) updated their guidelines on drug management for chronic heart failure. The guidelines recommend first-line therapy with both an ACE-inhibitor and a beta-blocker, with clinical judgement used to determine which one to start first. Second-line therapy involves the use of aldosterone antagonists, which should be monitored for hyperkalaemia. SGLT-2 inhibitors are also increasingly being used to manage heart failure with a reduced ejection fraction. Third-line therapy should be initiated by a specialist and may include ivabradine, sacubitril-valsartan, hydralazine in combination with nitrate, digoxin, or cardiac resynchronisation therapy. Other treatments such as annual influenza and one-off pneumococcal vaccines are also recommended.

Overall, the NICE guidelines provide a comprehensive approach to drug management for chronic heart failure. It is important to note that loop diuretics have not been shown to reduce mortality in the long-term, and that ACE-inhibitors and beta-blockers have no effect on mortality in heart failure with preserved ejection fraction. Healthcare professionals should carefully consider the patient’s individual needs and circumstances when determining the appropriate drug therapy for chronic heart failure.

The National Institute for Clinical Excellence updated its guideline for hypertension management in 2011, placing emphasis on the use of ambulatory blood pressure monitoring (ABPM) to confirm hypertension in individuals with elevated clinic readings. ABPM involves taking two measurements per hour during waking hours and using the average of at least 14 measurements to confirm a diagnosis of hypertension. Secondary causes of hypertension should be investigated in patients under 40 without traditional risk factors, those with other symptoms of secondary causes, and those with resistant hypertension. Hyperaldosteronism is the most common cause of secondary hypertension, and a trial of spironolactone may be used for both therapeutic and diagnostic purposes. Drug treatment for essential hypertension involves ACE inhibitors for those under 55 and calcium channel blockers for those over 55 or of black African or Caribbean origin. Step 2 involves using both ACE inhibitors and calcium channel blockers, while step 3 adds a thiazide-like diuretic. Further diuretics, beta-blockers, or alpha blockers may be considered in step 4, with expert advice sought. For a more detailed explanation, refer to the provided link.

NICE released updated guidelines in 2019 for the management of hypertension, building on previous guidelines from 2011. These guidelines aimed to classify hypertension into stages and recommend the use of ambulatory blood pressure monitoring (ABPM) and home blood pressure monitoring (HBPM) to accurately diagnose hypertension. This is important because some patients experience white coat hypertension, where their blood pressure rises in a clinical setting, leading to potential overdiagnosis of hypertension. ABPM and HBPM allow for a more accurate assessment of a patient’s overall blood pressure and can prevent overdiagnosis.

NICE recommends measuring blood pressure in both arms when considering a diagnosis of hypertension and repeating measurements if there is a difference of more than 20 mmHg between arms. If the blood pressure is >= 140/90 mmHg, NICE suggests offering ABPM or HBPM to confirm the diagnosis. If the blood pressure is >= 180/120 mmHg, referral for specialist assessment is recommended if there are signs of retinal haemorrhage or papilloedema or life-threatening symptoms. If target organ damage is identified, antihypertensive drug treatment may be started immediately.

ABPM involves taking at least 2 measurements per hour during the person’s usual waking hours and using the average value of at least 14 measurements. If ABPM is not tolerated, HBPM should be offered. HBPM involves taking two consecutive measurements at least 1 minute apart, twice daily for at least 4 days, and using the average value of all remaining measurements.

Interpreting the results of ABPM/HBPM is important for determining treatment. If the average blood pressure is >= 135/85 mmHg (stage 1 hypertension), treatment may be considered for patients under 80 years of age with target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. In 2019, NICE also recommended considering antihypertensive drug treatment for adults under 60 with stage 1 hypertension and an estimated 10-year risk below 10%. If the average blood pressure is >= 150/95 mmHg (stage 2 hypertension), drug treatment should be offered regardless of age.

Differentiating Causes of Syncope: A Guide

Syncope, or fainting, can be caused by a variety of underlying conditions. One such condition is hypertrophic cardiomyopathy (HCM), which often presents with syncope following exercise. Patients with HCM may also have a mid-systolic murmur and a jerky pulse, which worsens with Valsalva but improves with squatting.

Atrial fibrillation, on the other hand, typically presents with palpitations, fatigue, or shortness of breath, but not syncope. It does not cause a murmur and results in an irregularly irregular pulse.

Epilepsy is not a common cause of syncope, as typical seizures involve loss of consciousness, tensing, shaking, and postictal fatigue.

Aortic stenosis can cause dizziness and syncope, and is usually associated with angina. The murmur associated with aortic stenosis is a crescendo-decrescendo murmur that radiates to the carotids.

A vasovagal attack, while it can cause syncope, would not cause a murmur. If syncope is recurrent, other causes should be sought.

Dyspnea is a common complaint in patients with HCM, but they may also experience angina or syncope. A left ventricular apical impulse, a prominent S4 gallop, and a harsh systolic ejection murmur are typical findings. The Valsalva maneuver can increase the murmur. An echocardiogram is the diagnostic procedure of choice.

Most patients with aortic stenosis have gradually increasing obstruction for years but do not become symptomatic until their sixth to eighth decades.

Possible Causes of Hypertension: Differential Diagnosis

Hypertension in a young patient may indicate a secondary cause, such as renovascular disease. In this case, a small kidney on ultrasound and elevated creatinine levels suggest renal artery stenosis as a possible cause. Other potential diagnoses, such as Cushing’s syndrome, acromegaly, and phaeochromocytoma, are less likely based on the absence of corresponding symptoms and signs. Polycystic kidney disease, which can also cause hypertension, would typically present with bilateral renal enlargement rather than atrophy. A thorough differential diagnosis is important to identify the underlying cause of hypertension and guide appropriate management.

The recommended first-line treatment for patients with heart failure with reduced LVEF is a combination of a beta blocker and an ACE inhibitor. In this case, bisoprolol and ramipril are the appropriate medications to prescribe. The patient’s symptoms, medical history, and reduced left ventricular ejection fraction support this treatment plan. Amlodipine and ramipril, bisoprolol and amlodipine, and bisoprolol and furosemide are not recommended as initial treatments for heart failure with reduced LVEF.

Drug Management for Chronic Heart Failure: NICE Guidelines

Chronic heart failure is a serious condition that requires proper management to improve patient outcomes. In 2018, the National Institute for Health and Care Excellence (NICE) updated their guidelines on drug management for chronic heart failure. The guidelines recommend first-line therapy with both an ACE-inhibitor and a beta-blocker, with clinical judgement used to determine which one to start first. Second-line therapy involves the use of aldosterone antagonists, which should be monitored for hyperkalaemia. SGLT-2 inhibitors are also increasingly being used to manage heart failure with a reduced ejection fraction. Third-line therapy should be initiated by a specialist and may include ivabradine, sacubitril-valsartan, hydralazine in combination with nitrate, digoxin, or cardiac resynchronisation therapy. Other treatments such as annual influenza and one-off pneumococcal vaccines are also recommended.

Overall, the NICE guidelines provide a comprehensive approach to drug management for chronic heart failure. It is important to note that loop diuretics have not been shown to reduce mortality in the long-term, and that ACE-inhibitors and beta-blockers have no effect on mortality in heart failure with preserved ejection fraction. Healthcare professionals should carefully consider the patient’s individual needs and circumstances when determining the appropriate drug therapy for chronic heart failure.

For the management of STEMI, guidelines recommend primary PCI within 120 minutes of presentation or within 12 hours of symptom onset. As this patient presented with 10 hours of pain and transfer to the nearest hospital for PCI would take 3 hours, fibrinolysis should be offered instead. Giving unfractionated heparin and a glycoprotein IIb/IIIa inhibitor is inappropriate in this case. The patient should not be immediately transferred for PCI, but if the ST elevation is not resolved on a repeat ECG taken 90 minutes after fibrinolysis, then transfer for PCI should be considered. Rechecking troponin in 120 minutes is not necessary, and repeating an ECG in 120 minutes is not the next most important step. Administering fibrinolysis and taking a repeat ECG at the 90-minute mark are the appropriate next steps.

Managing Acute Coronary Syndrome: A Summary of NICE Guidelines

Acute coronary syndrome (ACS) is a common and serious medical condition that requires prompt management. The management of ACS has evolved over the years, with the development of new drugs and procedures such as percutaneous coronary intervention (PCI). The National Institute for Health and Care Excellence (NICE) has updated its guidelines on the management of ACS in 2020.

ACS can be classified into three subtypes: ST-elevation myocardial infarction (STEMI), non ST-elevation myocardial infarction (NSTEMI), and unstable angina. The management of ACS depends on the subtype. However, there are common initial drug therapies for all patients with ACS, such as aspirin and nitrates. Oxygen should only be given if the patient has oxygen saturations below 94%, and morphine should only be given for severe pain.

For patients with STEMI, the first step is to assess eligibility for coronary reperfusion therapy, which can be either PCI or fibrinolysis. Patients with NSTEMI/unstable angina require a risk assessment using the Global Registry of Acute Coronary Events (GRACE) tool to determine whether they need coronary angiography (with follow-on PCI if necessary) or conservative management.

This summary provides an overview of the NICE guidelines for managing ACS. The guidelines are complex and depend on individual patient factors, so healthcare professionals should review the full guidelines for further details. Proper management of ACS can improve patient outcomes and reduce the risk of complications.

A prolonged QT interval may be caused by Erythromycin.

Understanding Long QT Syndrome

Long QT syndrome (LQTS) is a genetic condition that causes delayed repolarization of the ventricles, which can lead to ventricular tachycardia and sudden death. The most common types of LQTS are caused by defects in the alpha subunit of the slow delayed rectifier potassium channel. A normal corrected QT interval is less than 430 ms in males and 450 ms in females.

There are various causes of a prolonged QT interval, including congenital factors, drugs, and other medical conditions. Some drugs that can prolong the QT interval include amiodarone, tricyclic antidepressants, and selective serotonin reuptake inhibitors. Electrolyte imbalances, acute myocardial infarction, and subarachnoid hemorrhage can also cause a prolonged QT interval.

LQTS may be picked up on routine ECG or following family screening. The symptoms and events associated with LQTS can vary depending on the type of LQTS. Long QT1 is usually associated with exertional syncope, while Long QT2 is often associated with syncope following emotional stress or exercise. Long QT3 events often occur at night or at rest.

Management of LQTS involves avoiding drugs that prolong the QT interval and other precipitants if appropriate. Beta-blockers may be used, and in high-risk cases, implantable cardioverter defibrillators may be necessary. It is important to recognize and manage LQTS to prevent sudden cardiac death.

Treatment Options for Heart Failure: A Summary of Medications and Their Effects

Heart failure is a serious condition that requires careful management to improve symptoms and reduce mortality rates. Two medications that have been found to be effective in reducing mortality are β-blockers and ACE inhibitors. These medications work by reducing afterload and should be offered as first-line treatment according to NICE guidelines. Loop diuretics, on the other hand, have no mortality benefit but can provide symptomatic relief. Digoxin, while effective in providing symptomatic relief, has been found to increase mortality rates and should be used with caution. Spironolactone, however, has been shown to greatly reduce mortality and sudden cardiac death rates and should be added to the treatment. Finally, while angiotensin II receptor antagonists can be used in patients who are intolerant of ACE inhibitors or added to ACE inhibitors and β-blockers if patients remain symptomatic, ACE inhibitors have been found to result in better prognosis. It is important to carefully consider the benefits and risks of each medication when treating patients with heart failure.

Anteroseptal changes in V1-V4 indicate involvement of the left anterior descending artery.
Inferior changes in II, III, and aVF suggest the right coronary artery is affected.
Anterolateral changes in V1-6, I, and aVL indicate the proximal left anterior descending artery is involved.
Lateral changes in I, aVL, and possibly V5-6 suggest the left circumflex artery is affected.
Posterior changes in V1-3 may indicate a posterior infarction, which is confirmed by ST elevation and Q waves in posterior leads (V7-9). This type of infarction is usually caused by the left circumflex artery, but can also be caused by the right coronary artery.
Reciprocal changes of STEMI are typically seen as horizontal ST depression, tall and broad R waves, upright T waves, and a dominant R wave in V2. It is important to note that a new left bundle branch block (LBBB) may indicate acute coronary syndrome.

Overall, understanding the correlation between ECG changes and coronary artery territories is crucial in diagnosing acute coronary syndrome. By identifying the specific changes in the ECG, medical professionals can determine which artery is affected and provide appropriate treatment. Additionally, recognizing the reciprocal changes of STEMI and the significance of a new LBBB can aid in making an accurate diagnosis.

Understanding Abdominal Aortic Aneurysms

Abdominal aortic aneurysms occur when the elastic proteins within the extracellular matrix fail, causing dilation of all layers of the arterial wall. This degenerative disease is most commonly seen in individuals over the age of 50, with diameters of 3 cm or greater considered aneurysmal. The development of aneurysms is a complex process involving the loss of the intima and elastic fibers from the media, which is associated with increased proteolytic activity and lymphocytic infiltration.

Smoking and hypertension are major risk factors for the development of aneurysms, while rare causes include syphilis and connective tissue diseases such as Ehlers Danlos type 1 and Marfan’s syndrome. It is important to understand the pathophysiology of abdominal aortic aneurysms in order to identify and manage risk factors, as well as to provide appropriate treatment for those affected. By recognizing the underlying causes and risk factors, healthcare professionals can work to prevent the development of aneurysms and improve outcomes for those affected.

Young athletes with hypertrophic obstructive cardiomyopathy are at risk of sudden death due to ventricular arrhythmia. This is believed to be caused by ventricular tachycardia resulting from ischaemia, which typically occurs during extreme exertion. Unlike myocardial infarction, which is commonly associated with atherosclerosis in the coronary arteries, it is unlikely for a young person to develop this condition. However, cocaine use may increase the risk of MI in young people. Although HOCM may cause a regurgitant mitral valve, valve rupture is not a known complication. While heart block may occur in some cases of HOCM, it is rare and is unlikely to cause sudden death.

Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder that affects muscle tissue and is caused by mutations in genes encoding contractile proteins. It is characterized by left ventricle hypertrophy, diastolic dysfunction, and myofibrillar hypertrophy with disarray and fibrosis on biopsy. HOCM can be asymptomatic or present with exertional dyspnea, angina, syncope, sudden death, arrhythmias, heart failure, jerky pulse, and systolic murmurs. It is associated with Friedreich’s ataxia and Wolff-Parkinson White. ECG findings include left ventricular hypertrophy, non-specific ST segment and T-wave abnormalities, and deep Q waves.

The symptoms of pruritus and pain that gradually worsen, along with the results of the examination, indicate a high likelihood of post-thrombotic syndrome.

Post-Thrombotic Syndrome: A Complication of Deep Vein Thrombosis

Post-thrombotic syndrome is a clinical syndrome that may develop following a deep vein thrombosis (DVT). It is caused by venous outflow obstruction and venous insufficiency, which leads to chronic venous hypertension. Patients with post-thrombotic syndrome may experience painful, heavy calves, pruritus, swelling, varicose veins, and venous ulceration.

In the past, compression stockings were offered to patients with DVT to reduce the risk of post-thrombotic syndrome. However, current recommendations state that elastic graduated compression stockings should not be used to prevent post-thrombotic syndrome or VTE recurrence after a proximal DVT. This recommendation does not cover the use of elastic stockings for the management of leg symptoms after DVT.

Once post-thrombotic syndrome has developed, compression stockings are a recommended treatment. Other recommendations include keeping the leg elevated. It is important for healthcare providers to recognize the potential complications of DVT and to provide appropriate management to prevent the development of post-thrombotic syndrome.

Differentiating Vascular Conditions: Causes and Symptoms

Cholesterol embolisation occurs when cholesterol crystals from a ruptured atherosclerotic plaque block small or medium arteries, often following an intervention like coronary angiography. This results in microvascular ischemia, which typically does not affect blood pressure or larger vessels, explaining the normal peripheral pulses in affected patients. Livedo reticularis, a purplish discoloration, may also occur due to microvascular ischemia.

Arterial thromboembolism is a common condition, especially in patients with established cardiovascular disease or risk factors like hypertension, hyperlipidemia, and smoking. It tends to affect larger vessels than cholesterol embolism, leading to the absence of peripheral pulses and gangrenous toes.

Buerger’s disease, also known as thromboangiitis obliterans, is a vasculitis that mainly affects young men who smoke. It presents with claudication of the arms or legs, with or without ulcers or gangrene. However, the acute onset of symptoms following an intervention makes cholesterol embolism a more likely diagnosis.

Deep vein thrombosis typically presents with a swollen, painful calf and does not display signs of arterial insufficiency like gangrene and livedo reticularis.

Takayasu’s arteritis is a rare form of large vessel vasculitis that mainly affects the aorta. It is more common in women and tends to present below the age of 30 years old with pulseless arms. However, this patient’s history is not typical for Takayasu’s arteritis.

Bedside Abdominal Ultrasound for Ruptured Abdominal Aortic Aneurysm: Diagnosis and Management

This patient is likely experiencing a ruptured abdominal aortic aneurysm (AAA), a life-threatening medical emergency. Bedside abdominal ultrasound (US) is the best initial diagnostic test for ruling out AAA as a cause of abdominal or back pain, as it provides an instant, objective measurement of aortic diameter. An AAA is a dilatation of the abdominal aorta greater than 3 cm in diameter, with a significant risk of rupture at diameters greater than 5 cm. Risk factors for AAA include smoking and co-existing vascular disease. Symptoms of a ruptured AAA include pain, cardiovascular failure, and distal ischemia. Once diagnosed, a CT angiogram is the gold-standard imaging for planning surgery to repair the aneurysm. Endoscopic retrograde cholangiopancreatography and liver function tests are not indicated in this case, while serum amylase or lipase should be measured in all patients presenting with acute abdominal or upper back pain to exclude acute pancreatitis as a differential diagnosis.

Chronic heart failure is a condition that requires proper diagnosis and management. In 2018, NICE updated their guidelines on the diagnosis and management of this condition. Previously, the first-line investigation was determined by whether the patient had previously had a myocardial infarction or not. However, this is no longer the case. All patients should now have an N-terminal pro-B-type natriuretic peptide (NT‑proBNP) blood test as the first-line investigation.

Interpreting the NT-proBNP blood test is crucial in determining the severity of the condition. If the levels are high, specialist assessment, including transthoracic echocardiography, should be arranged within two weeks. If the levels are raised, specialist assessment, including echocardiogram, should be arranged within six weeks. B-type natriuretic peptide (BNP) is a hormone produced mainly by the left ventricular myocardium in response to strain. Very high levels of BNP are associated with a poor prognosis.

There are different levels of BNP, and each level indicates a different severity of the condition. High levels of BNP are greater than 400 pg/ml (116 pmol/litre) for BNP and greater than 2000 pg/ml (236 pmol/litre) for NTproBNP. Raised levels of BNP are between 100-400 pg/ml (29-116 pmol/litre) for BNP and between 400-2000 pg/ml (47-236 pmol/litre) for NTproBNP. Normal levels of BNP are less than 100 pg/ml (29 pmol/litre) for BNP and less than 400 pg/ml (47 pmol/litre) for NTproBNP.

It is important to note that several factors can alter the BNP level. Factors that increase BNP levels include left ventricular hypertrophy, ischaemia, tachycardia, right ventricular overload, hypoxaemia (including pulmonary embolism), GFR < 60 ml/min, sepsis, COPD, diabetes, and age > 70. On the other hand, factors that decrease BNP levels include diuretics, ACE inhibitors, beta-blockers, angiotensin 2 receptor blockers, and aldosterone antagonists.

In the case of pulseless electrical activity, which is a non-shockable rhythm, the ALS algorithm requires the administration of adrenaline as soon as intravascular access is achieved. This should be done immediately after the rhythm check, following two more minutes of CPR. The recommended dose is 1mg IV, which should be repeated every 3-5 minutes. It is important to note that intramuscular adrenaline is not appropriate for cardiac arrest, and IV amiodarone is not indicated for non-shockable rhythms. While it is correct to avoid shocking the patient, it is incorrect to delay drug administration until the next rhythm check. The most recent Resuscitation Council Guidelines (2021) support the immediate administration of adrenaline in non-shockable rhythms.

The 2015 Resus Council guidelines for adult advanced life support outline the steps to be taken when dealing with patients with shockable and non-shockable rhythms. For both types of patients, chest compressions are a crucial part of the process, with a ratio of 30 compressions to 2 ventilations. Defibrillation is recommended for shockable rhythms, with a single shock for VF/pulseless VT followed by 2 minutes of CPR. Adrenaline and amiodarone are the drugs of choice for non-shockable rhythms, with adrenaline given as soon as possible and amiodarone administered after 3 shocks for VF/pulseless VT. Thrombolytic drugs should be considered if a pulmonary embolus is suspected. Atropine is no longer recommended for routine use in asystole or PEA. Oxygen should be titrated to achieve saturations of 94-98% following successful resuscitation. The Hs and Ts should be considered as potential reversible causes of cardiac arrest.

The National Institute for Health and Care Excellence recommends using a β blocker or calcium channel blocker as the first-line treatment for angina, along with a statin. If a patient is intolerant to β blockers or not responding to a CCB alone, a long-acting nitrate can be added. An ACE inhibitor is not indicated for angina treatment. Beta blockers and CCBs can be used together if one alone does not control symptoms, but caution is needed to avoid conduction problems. Long-acting nitrates should only be used in isolation if CCB or β blocker use is contraindicated. Aspirin is recommended for secondary prevention, and short-acting nitrates can be used for symptom relief. The 4S study showed that statins significantly reduce the risk of MI in patients with angina and high cholesterol levels.

An ST-elevated myocardial infarction affecting the inferior leads (II, III, aVF) can cause arrhythmias due to the involvement of the right coronary artery, which supplies blood to the AV node. This is evidenced by the patient’s presentation with 1st-degree heart block following the MI.

Anteroseptal changes in V1-V4 indicate involvement of the left anterior descending artery. Inferior changes in II, III, and aVF suggest the right coronary artery is affected. Anterolateral changes in V1-6, I, and aVL indicate the proximal left anterior descending artery is involved. Lateral changes in I, aVL, and possibly V5-6 suggest the left circumflex artery is affected. Posterior changes in V1-3 may indicate a posterior infarction, which is confirmed by ST elevation and Q waves in posterior leads (V7-9). This type of infarction is usually caused by the left circumflex artery, but can also be caused by the right coronary artery. Reciprocal changes of STEMI are typically seen as horizontal ST depression, tall and broad R waves, upright T waves, and a dominant R wave in V2. It is important to note that a new left bundle branch block (LBBB) may indicate acute coronary syndrome.

Overall, understanding the correlation between ECG changes and coronary artery territories is crucial in diagnosing acute coronary syndrome. By identifying the specific changes in the ECG, medical professionals can determine which artery is affected and provide appropriate treatment. Additionally, recognizing the reciprocal changes of STEMI and the significance of a new LBBB can aid in making an accurate diagnosis.

The current treatment plan of prescribing fondaparinux, clopidogrel, and scheduling a coronary angiography in 3 months is incorrect. Clopidogrel is typically prescribed for patients with a higher risk of bleeding or those taking an oral anticoagulant. Additionally, delaying definitive treatment for a high-risk patient by scheduling a coronary angiography in 3 months could lead to increased mortality. Instead, a more appropriate treatment plan would involve prescribing prasugrel, unfractionated heparin, and a glycoprotein IIB/IIIA inhibitor, and referring the patient for urgent PCI within 2 hours. However, it should be noted that this treatment plan is specific to patients with STEMI and access to PCI facilities.

Managing Acute Coronary Syndrome: A Summary of NICE Guidelines

Acute coronary syndrome (ACS) is a common and serious medical condition that requires prompt management. The management of ACS has evolved over the years, with the development of new drugs and procedures such as percutaneous coronary intervention (PCI). The National Institute for Health and Care Excellence (NICE) has updated its guidelines on the management of ACS in 2020.

ACS can be classified into three subtypes: ST-elevation myocardial infarction (STEMI), non ST-elevation myocardial infarction (NSTEMI), and unstable angina. The management of ACS depends on the subtype. However, there are common initial drug therapies for all patients with ACS, such as aspirin and nitrates. Oxygen should only be given if the patient has oxygen saturations below 94%, and morphine should only be given for severe pain.

For patients with STEMI, the first step is to assess eligibility for coronary reperfusion therapy, which can be either PCI or fibrinolysis. Patients with NSTEMI/unstable angina require a risk assessment using the Global Registry of Acute Coronary Events (GRACE) tool to determine whether they need coronary angiography (with follow-on PCI if necessary) or conservative management.

This summary provides an overview of the NICE guidelines for managing ACS. The guidelines are complex and depend on individual patient factors, so healthcare professionals should review the full guidelines for further details. Proper management of ACS can improve patient outcomes and reduce the risk of complications.

In cases of haemodynamically stable patients with SVT who do not respond to vagal manoeuvres, the recommended course of action is to administer adenosine.

Understanding Supraventricular Tachycardia

Supraventricular tachycardia (SVT) is a type of tachycardia that originates above the ventricles. It is commonly associated with paroxysmal SVT, which is characterized by sudden onset of a narrow complex tachycardia, usually an atrioventricular nodal re-entry tachycardia (AVNRT). Other causes include atrioventricular re-entry tachycardias (AVRT) and junctional tachycardias.

When it comes to acute management, vagal maneuvers such as the Valsalva maneuver or carotid sinus massage can be used. Intravenous adenosine is also an option, with a rapid IV bolus of 6mg given initially, followed by 12mg and then 18mg if necessary. However, adenosine is contraindicated in asthmatics, and verapamil may be a better option for them. Electrical cardioversion is another option.

To prevent episodes of SVT, beta-blockers can be used. Radio-frequency ablation is also an option. It is important to work with a healthcare provider to determine the best course of treatment for each individual case.

Overall, understanding SVT and its management options can help individuals with this condition better manage their symptoms and improve their quality of life.

In a witnessed cardiac arrest with VF/VT rhythm, up to three quick successive shocks should be given before starting chest compressions. This is regarded as the first shock in the ALS algorithm. Adrenaline should be given every 3-5 minutes and a praecordial thump should only be used if a defibrillator is not available. Commencing CPR after just one shock would miss the opportunity to deliver three rapid shocks.

The 2015 Resus Council guidelines for adult advanced life support outline the steps to be taken when dealing with patients with shockable and non-shockable rhythms. For both types of patients, chest compressions are a crucial part of the process, with a ratio of 30 compressions to 2 ventilations. Defibrillation is recommended for shockable rhythms, with a single shock for VF/pulseless VT followed by 2 minutes of CPR. Adrenaline and amiodarone are the drugs of choice for non-shockable rhythms, with adrenaline given as soon as possible and amiodarone administered after 3 shocks for VF/pulseless VT. Thrombolytic drugs should be considered if a pulmonary embolus is suspected. Atropine is no longer recommended for routine use in asystole or PEA. Oxygen should be titrated to achieve saturations of 94-98% following successful resuscitation. The Hs and Ts should be considered as potential reversible causes of cardiac arrest.

To prevent angina attacks, the first-line treatment is either a beta-blocker or a calcium channel blocker. If a person experiences chest pain that feels like squeezing during physical activity but goes away with rest, it is likely stable angina. Having high cholesterol levels increases the risk of developing this condition. A normal electrocardiogram (ECG) indicates that there is no ongoing heart attack.

Angina pectoris is a condition that can be managed through various methods, including lifestyle changes, medication, percutaneous coronary intervention, and surgery. In 2011, NICE released guidelines for the management of stable angina. Medication is an important aspect of treatment, and all patients should receive aspirin and a statin unless there are contraindications. Sublingual glyceryl trinitrate can be used to abort angina attacks. The first-line medication should be either a beta-blocker or a calcium channel blocker, depending on the patient’s comorbidities, contraindications, and preferences. If a calcium channel blocker is used as monotherapy, a rate-limiting one such as verapamil or diltiazem should be used. If used in combination with a beta-blocker, a longer-acting dihydropyridine calcium channel blocker should be used. Beta-blockers should not be prescribed concurrently with verapamil due to the risk of complete heart block. If the initial treatment is not effective, medication should be increased to the maximum tolerated dose. If a patient is still symptomatic after monotherapy with a beta-blocker, a calcium channel blocker can be added, and vice versa. If a patient cannot tolerate the addition of a calcium channel blocker or a beta-blocker, other drugs such as long-acting nitrates, ivabradine, nicorandil, or ranolazine can be considered. Nitrate tolerance is a common issue, and patients who take standard-release isosorbide mononitrate should use an asymmetric dosing interval to maintain a daily nitrate-free time of 10-14 hours to minimize the development of nitrate tolerance. This effect is not seen in patients who take once-daily modified-release isosorbide mononitrate. If a patient is taking both a beta-blocker and a calcium-channel blocker, a third drug should only be added while awaiting assessment for PCI or CABG.

Infective endocarditis is a serious infection of the heart lining and valves. The 2008 guidelines from NICE have changed the list of procedures for which antibiotic prophylaxis is recommended. According to NICE, dental procedures, gastrointestinal, genitourinary, and respiratory tract procedures do not require prophylaxis. However, if a person at risk of infective endocarditis is receiving antimicrobial therapy because they are undergoing a gastrointestinal or genitourinary procedure at a site where there is a suspected infection, they should be given an antibiotic that covers organisms that cause infective endocarditis. It is important to note that these recommendations differ from the American Heart Association/European Society of Cardiology guidelines, which still advocate antibiotic prophylaxis for high-risk patients undergoing dental procedures.

The guidelines suggest that any episodes of infection in people at risk of infective endocarditis should be investigated and treated promptly to reduce the risk of endocarditis developing. It is crucial to follow these guidelines to prevent the development of infective endocarditis, which can lead to severe complications and even death. It is also important to note that these guidelines may change over time as new research and evidence become available. Therefore, healthcare professionals should stay up-to-date with the latest recommendations to provide the best possible care for their patients.

Patients diagnosed with superficial thrombophlebitis in the long saphenous vein should undergo an ultrasound scan to rule out the possibility of an underlying DVT. While this condition is typically harmless and can be treated with NSAIDs and compression, it carries a risk of DVT and subsequent PE. Therefore, it is recommended that patients with proximal long saphenous vein thrombophlebitis undergo an ultrasound to exclude DVT.

In this case, there are no indications of PE or respiratory symptoms, so a CTPA or chest X-ray is not necessary. While a D-dimer test is typically used to diagnose DVT, it is not useful in the presence of superficial thrombophlebitis. As a result, the guideline is to proceed directly to venous ultrasound.

The risk factors for superficial thrombophlebitis are the same as those for DVT/PE, such as female sex, prolonged immobility, obesity, and cancer. While checking blood lipid levels may be relevant, it is not a primary concern as this is a thrombotic rather than an atherosclerotic process.

Superficial thrombophlebitis is inflammation associated with thrombosis of a superficial vein, usually the long saphenous vein of the leg. Around 20% of cases have an underlying deep vein thrombosis (DVT) and 3-4% may progress to a DVT if untreated. Treatment options include NSAIDs, topical heparinoids, compression stockings, and low-molecular weight heparin. Patients with clinical signs of superficial thrombophlebitis affecting the proximal long saphenous vein should have an ultrasound scan to exclude concurrent DVT. Patients with superficial thrombophlebitis at, or extending towards, the sapheno-femoral junction can be considered for therapeutic anticoagulation for 6-12 weeks.

For a newly diagnosed patient of black African or African-Caribbean origin with hypertension, adding a calcium channel blocker (CCB) such as nifedipine is recommended as the first-line treatment. This is because ACE inhibitors and ARBs are less effective in patients of these ethnicities. Lifestyle advice alone is not sufficient if the patient’s average blood pressure reading on ambulatory monitoring is greater than 150/95 mmHg. Ramipril is not the first-line option for this patient population, and Losartan is a second-line option after CCBs.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

For a newly diagnosed patient with hypertension and a history of type 2 diabetes mellitus, it is recommended to add an ACE inhibitor or an angiotensin receptor blocker regardless of age. In this case, Ramipril, an ACE inhibitor, would be the appropriate choice. However, if the patient did not have a history of type 2 diabetes, the initial management would be to prescribe a calcium channel blocker such as amlodipine, especially if the patient is over 55 years old. If the blood pressure remains high, a thiazide-like diuretic or calcium channel blocker can be added to the ACE inhibitor. If the blood pressure still remains elevated, a combination of ACE inhibitor, calcium channel blocker, and thiazide-like diuretic can be considered. Indapamide is a thiazide-like diuretic that can be used in combination with an ACE inhibitor or as an additional therapy with an ACE inhibitor and calcium channel blocker if the blood pressure is not well controlled. Bisoprolol, a beta-blocker, can also be considered if the blood pressure remains high despite the combination of ACE inhibitor, calcium channel blocker, and thiazide-like diuretic.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

For the treatment of hypertension in diabetic patients, the first-line medication should be ACE inhibitors such as ramipril. However, this may not be suitable for individuals of Afro-Caribbean descent or women who may become pregnant. In case of a cough developing with ACE inhibitors, an angiotensin-II receptor antagonist like losartan should be prescribed. If the patient is not diabetic, calcium channel blockers like amlodipine or diuretics such as indapamide would be the preferred initial treatment. Beta blockers like propranolol are not typically the first choice for hypertension treatment, but may be considered for young patients who cannot tolerate ACE inhibitors or women attempting to conceive.

NICE released updated guidelines in 2019 for the management of hypertension, building on previous guidelines from 2011. These guidelines aimed to classify hypertension into stages and recommend the use of ambulatory blood pressure monitoring (ABPM) and home blood pressure monitoring (HBPM) to accurately diagnose hypertension. This is important because some patients experience white coat hypertension, where their blood pressure rises in a clinical setting, leading to potential overdiagnosis of hypertension. ABPM and HBPM allow for a more accurate assessment of a patient’s overall blood pressure and can prevent overdiagnosis.

NICE recommends measuring blood pressure in both arms when considering a diagnosis of hypertension and repeating measurements if there is a difference of more than 20 mmHg between arms. If the blood pressure is >= 140/90 mmHg, NICE suggests offering ABPM or HBPM to confirm the diagnosis. If the blood pressure is >= 180/120 mmHg, referral for specialist assessment is recommended if there are signs of retinal haemorrhage or papilloedema or life-threatening symptoms. If target organ damage is identified, antihypertensive drug treatment may be started immediately.

ABPM involves taking at least 2 measurements per hour during the person’s usual waking hours and using the average value of at least 14 measurements. If ABPM is not tolerated, HBPM should be offered. HBPM involves taking two consecutive measurements at least 1 minute apart, twice daily for at least 4 days, and using the average value of all remaining measurements.

Interpreting the results of ABPM/HBPM is important for determining treatment. If the average blood pressure is >= 135/85 mmHg (stage 1 hypertension), treatment may be considered for patients under 80 years of age with target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. In 2019, NICE also recommended considering antihypertensive drug treatment for adults under 60 with stage 1 hypertension and an estimated 10-year risk below 10%. If the average blood pressure is >= 150/95 mmHg (stage 2 hypertension), drug treatment should be offered regardless of age.